PBPCT and 75% for BMT (P = 0.8). Differences between total days of acute GVHD and the GVHD score (calculated by summating the figures produced from multiplying each grade of acute GVHD experienced by the number of days at that grade) were also not statistically significant. The incidence of acute GVHD of grade II or higher at day 100 post transplant was 31% in both groups (P = 0.99).
Analysis of chronic GVHD (defined as clinical GVHD occurring after day +100, Table 1 ) shows increased incidence in the PBPCT group (P = 0.02), occurring in all evaluable patients in this group. The increase is observed in clinically extensive chronic GVHD (P = 0.03) and, when analysed by body distribution, chronic GVHD of the eyes and/or mouth (P = 0.02). There were three deaths due to chronic GVHD in the PBPCT groups compared with one in the BMT control group.
In conclusion, although numbers are relatively small, this carefully matched retrospective analysis is supportive of an increased incidence of chronic GVHD with no apparent long-term survival benefit compared with BMT. The influence of methotrexate in GVHD prophylaxis has been previously discussed as a factor in explaining the conflicting results in previous studies, 1 and this may be relevant in the present study where a reduced dose was used. 5 Prospective randomised controlled trials are now in progress which should provide more definitive data. Analysis should account not only for the incidence of chronic GVHD generally but also for the pattern of organ involvement which may be significant in influencing overall survival and quality of life following allogeneic PBPCT.
First report of Epstein-Barr virus lymphoproliferative disease after cord blood transplantation
Epstein-Barr virus-associated lymphoproliferative disease (EBV-LPD) has emerged as a commonly fatal complication of allogeneic bone marrow transplantation (BMT).
1 Cord blood (CB) is an alternative source of hematopoietic stem cells for transplantation to treat hematologic disorders. 2 We report the first case of EBV-LPD following CB transplantation (CBT).
A 3-year-old girl in second complete remission of pre-B acute lymphoblastic leukemia (ALL) underwent CBT using an unmanipulated unrelated 5/6 HLA matched CB. HLA-DPB1 genotyping was DPB1*0401, DPB1*1101 for recipient and DPB1*0401, DPB1*0501 for donor. The pretransplant conditioning regimen consisted of fractionated total body irradiation (12 Gy) with cyclophosphamide (60 mg/kg i.v. daily on days −5 and −4) and antithymocyte globulin (20 mg/kg daily on days −3 to −1). Cyclosporine in combination with high-dose corticosteroids (methylprednisolone: 5 mg/kg on days 5 to 9, 3 mg/kg on days 10 and 11, then tapered 10% per week and stopped at day 110) was used for graft-versus-host disease (GVHD) prophylaxis. The recipient was EBV seropositive before CBT; the EBV genome was absent from the CB. No GVHD occurred. Engraftment was delayed, with hematologic recovery occurring at around day 100, but complete chimerism was proven by HLA-DPB1* genotyping: DPB1*0401, DPB1*0501. Around day +180, when cyclosporine was being tapered, the patient developed fever and neurologic disturbances. Contrast-enhanced T2-weighted magnetic resonance imaging of the brain revealed diffuse lesions of the two parieto-temporal and occipital lobes, and of the brain stem. EBV-DNA was detected by polymerase chain reaction within the CSF. The patient died from neurologic complications on day 216.
An autopsy was performed and histologic study of the brain revealed immunoblastic large-cell B lymphoma (CD20+); most cells expressed EBV-encoded latent membrane protein 1. These CNS lymphomatous cells were investigated using HLA-DPB1* genotyping and polymerase chain reaction amplification of a polymorphic DNA marker (D17S5); samples were analyzed by Southern blotting and showed a different pattern with the recipient CNS cells. These results indicated that the lymphoma was of donor origin: DPB1*0401, DPB1*0501, excluding an ALL relapse. Rare immunoblastic cells were also found in the spleen.
Risk 5 clearly showed that profound deficiencies of EBVspecific cytotoxic T cells in the post-transplantation setting are associated with an increasing risk of EBV-LPD. The absence of these EBV-specific cytotoxic T cells in naive CB cells could be one of the mechanisms responsible for the emergence of LPD in our patient. 
